Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
January 17, 2017 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
Kura Oncology Logo
Kura Oncology Appoints Steven Stein, M.D. to Board of Directors
January 03, 2017 16:05 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its...
Geron-logo-black-xsmall.png
Geron Corporation Reports Third Quarter 2016 Financial Results and Recent Events
November 03, 2016 16:05 ET | Geron Corporation
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2016 and recent events. For...
Geron-logo-black-xsmall.png
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
September 12, 2016 07:30 ET | Geron Corporation
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of...
Kura Oncology Logo
Kura Oncology to Participate in the 5th Annual Gateway Conference
September 02, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
June 16, 2016 17:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2...
Kura Oncology Logo
Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences...
Kura Oncology Logo
Kura Oncology to Participate in the Jefferies 2016 Healthcare Conference
June 03, 2016 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the Jefferies 2016...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2016 Financial Results
May 11, 2016 16:05 ET | Kura Oncology, Inc.
LA JOLLA, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Geron-logo-black-xsmall.png
Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
January 14, 2016 07:30 ET | Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...